Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study

Károly Kulich, Dorothy L Keininger, Brian Tiplady, Donald Banerji, Károly Kulich, Dorothy L Keininger, Brian Tiplady, Donald Banerji

Abstract

Background: Symptoms, particularly dyspnea, and activity limitation, have an impact on the health status and the ability to function normally in patients with chronic obstructive pulmonary disease (COPD).

Methods: To develop an electronic patient diary (eDiary), qualitative patient interviews were conducted from 2009 to 2010 to identify relevant symptoms and degree of bother due to symptoms. The eDiary was completed by a subset of 209 patients with moderate-to-severe COPD in the 26-week QVA149 SHINE study. Two morning assessments (since awakening and since the last assessment) and one evening assessment were made each day. Assessments covered five symptoms ("shortness of breath," "phlegm/mucus," "chest tightness," "wheezing," and "coughing") and two impact items ("bothered by COPD" and "difficulty with activities") and were scored on a 10-point numeric scale.

Results: Patient compliance with the eDiary was 90.4% at baseline and 81.3% at week 26. Correlations between shortness of breath and impact items were >0.95. Regression analysis showed that shortness of breath was a highly significant (P<0.0001) predictor of impact items. Exploratory factor analysis gave a single factor comprising all eDiary items, including both symptoms and impact items. Shortness of breath, the total score (including five symptoms and two impact items), and the five-item symptom score from the eDiary performed well, with good consistency and reliability. The eDiary showed good sensitivity to change, with a 0.6 points reduction in the symptoms scores (on a 0-10 point scale) representing a meaningful change.

Conclusion: The eDiary was found to be valid, reliable, and responsive. The high correlations obtained between "shortness of breath" and the ratings of "bother" and "difficulty with activities" confirmed the relevance of this symptom in patients with COPD. Future studies will be required to explore further psychometric properties and their ability to differentiate between COPD treatments.

Trial registration: ClinicalTrials.gov NCT01202188.

Keywords: QVA149; dyspnea; health status; patient-reported outcomes; psychometric assessment.

Figures

Figure 1
Figure 1
Frequency of occurrence (A) and severity of COPD symptoms (B) over the study period. Abbreviations: COPD, chronic obstructive pulmonary disease; E, evening diary; M1, morning diary: symptoms since awakening; M2, morning diary: symptoms since the last assessment.
Figure 2
Figure 2
Sensitivity to change of the eDiary at week 26. Abbreviations: eDiary, electronic patient diary; SGRQ, St George’s Respiratory Questionnaire.

References

    1. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
    1. Baldwin MJ, Kulich K, Tiplady B, Gwaltney C, Cline J. Evaluation of an electronic daily diary for measuring morning symptoms in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:A2517.
    1. Baldwin M, Kulich K, Tiplady B, Gwaltney C, Cline J. Symptoms and impact of COPD assessed by a handheld electronic diary; Poster presented at: 2013 Meeting of the European Respiratory Society; September 7–11, 2013; Barcelona, Spain. Poster P4903.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease, Inc; 2014. 2014. [Accessed July 11, 2014]. update [webpage on the Internet] Available from: .
    1. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48(12):1204–1213.
    1. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25–31.
    1. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2(4):137–144.
    1. Byrom B, Tiplady B, editors. ePRO: Electronic Solutions for Patient-Reported Data. Surrey: Gower; 2010.
    1. Ireland AM, Wiklund I, Hsieh R, Dale P, O’Rourke E. An electronic diary is shown to be more reliable than a paper diary: results from a randomized crossover study in patients with persistent asthma. J Asthma. 2012;49(9):952–960.
    1. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE. Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity. J Clin Epidemiol. 2014;67(1):108–113.
    1. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ. 2002;324(7347):1193–1194.
    1. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929–942.
    1. Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697–709.
    1. US Department of Health and Human Services Food and Drug Administration . Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: FDA; 2009. [Accessed February 18, 2014]. Available from: .
    1. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
    1. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
    1. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558–1567.
    1. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
    1. Baldwin MJ, Kulich K, Tiplady B, Gwaltney C, Cline J. Evaluation of an electronic daily diary for measuring morning symptoms in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:A2517.
    1. Baldwin M, Kulich K, Tiplady B, Gwaltney C, Cline J. Symptoms and impact of COPD assessed by a handheld electronic diary; Poster presented at: 2013 Meeting of the European Respiratory Society; September 7–11, 2013; Barcelona, Spain. Poster P4903.
    1. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest. 1992;102(2):395–401.
    1. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011;20(3):257–268.
    1. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–758.
    1. O’Connor BP. SPSS and SAS programs for determining the number of components using parallel analysis and velicer’s MAP test. Behav Res Methods Instrum Comput. 2000;32(3):396–402.
    1. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420–428.
    1. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–1285.
    1. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
    1. Kerns K, Decker SN. Multifactorial assessment of reading disability: identifying the best predictors. Percept Mot Skills. 1985;60(3):747–753.
    1. Fraenkel L, Falzer P, Fried T, et al. Measuring pain impact versus pain severity using a numeric rating scale. J Gen Intern Med. 2012;27(5):555–560.
    1. Morren M, van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary pain measurement using electronic diaries: a systematic review. Eur J Pain. 2009;13(4):354–365.
    1. Mahler DA, Ward J, Waterman LA, McCusker C, Zuwallack R, Baird JC. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136(6):1473–1479.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1977.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit